Full Breakdown
Medtronic Posts Strong FY27 Q1 Results, Raises Full-Year Outlook
9/1/2026, 8:44:35 PM
Core Event: FY27 First-Quarter Earnings Beat Expectations
Medtronic plc announced results for its first fiscal quarter of 2027, the period that ended July 31, 2026. Global revenue reached $9.756 billion, up 13.7 % year-over-year, surpassing analyst expectations of $9.55 billion. GAAP net income rose to $1.47 billion, and diluted earnings per share (EPS) were $1.14, a 40.7 % increase from the prior year. Adjusted EPS of $1.45 exceeded the market consensus of $1.39. The company also lifted its fiscal-2027 organic revenue growth guidance to 7.25 %–7.75 % (from 6.75 %–7.25 %) and raised the adjusted EPS outlook to $5.94–$6.00 per share (previously $5.90–$6.00).
Background & Context
Prior to the quarter, Medtronic had projected organic revenue growth of 6.75 %–7.25 % for FY27 and an adjusted EPS range of $5.90–$6.00. The stronger-than-expected first-quarter performance prompted the upward revision of both revenue-growth and earnings guidance.
Data & Statistics
- Revenue: $9.756 billion (13.7 % YoY) – reported by Medtronic.
- GAAP operating profit: $1.764 billion, operating margin 18.1 % (up 120 bps).
- Adjusted operating profit: $2.316 billion, adjusted margin 23.7 % (up 10 bps).
- Segment performance:
- Cardiovascular: $3.93 billion, revenue growth 19.5 % (organic 18.9 %).
- Neuroscience: $2.68 billion, growth 10.3 % (organic 9.3 %).
- Medical Surgical: $2.28 billion, growth 10.0 % (organic 10.2 %).
- Diabetes: $843 million, growth 16.9 % (organic 14.9 %).
- Free cash flow: $1.29 billion, more than double the prior-year $584 million.
Official Statements & Responses
Chief Financial Officer Thierry Pieton highlighted that “the combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance.” Both executives linked the results to efficient commercial execution, product innovation, and a robust R&D pipeline.
Strategic Investments and Partnerships
Medtronic announced several strategic moves alongside the earnings release:
- A $700 million investment in Cornerstone Robotics, securing rights to distribute the Sentire Surgical System in markets outside the United States where it holds regulatory approval.
- An up-to $80 million investment in Pi-Cardia Ltd., with an option to acquire the company for an estimated upfront price of up to $210 million plus potential earn-out payments.
- Completed acquisitions of Scientia Vascular and SPR Therapeutics, and expanded CE Mark indications for the Affera Mapping and Ablation System.
Conflicting Reports & Gaps
Sources differ slightly on the exact revenue figure for the quarter: TradingKey and TradingView cite $9.756 billion, RTTNews reports $9.76 billion, and ScanX rounds the number to $9.8 billion. All agree on a 13.7 % year-over-year increase, but the precise dollar amount varies across reports. No source provides a detailed breakdown of the $570 million organic growth boost attributed to the extra fiscal week.
Verbatim Quotes
- “The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance,” — Thierry Pieton, Medtronic chief financial officer
What’s Next
Medtronic projects adjusted EPS of $1.32–$1.34 for the second quarter of FY27, slightly below the consensus midpoint of $1.34. The company will continue integrating its recent acquisitions and expanding the distribution of the Sentire and Hugo robotic-assisted surgery systems, while monitoring the performance of its emerging structural-heart platform.
